<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006255</url>
  </required_header>
  <id_info>
    <org_study_id>CWRU2Y00</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CWRU-2Y00</secondary_id>
    <secondary_id>NCI-G00-1850</secondary_id>
    <nct_id>NCT00006255</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging-guided Thermal Radiofrequencey Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases</brief_title>
  <official_title>A Phase II Study of Magnetic Resonance Guided and Monitored Interstitial Thermal Radiofrequency Ablation of Primary Renal Cell Carcinoma, Hepatic Metastasis, and Other Sites of Solid Organ Tumor and Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiofrequency ablation uses high-frequency electric current to heat and kill&#xD;
      tumor cells. Magnetic resonance imaging-guided radiofrequency ablation may an effective&#xD;
      treatment for primary kidney cancer, liver metastases, or other solid tumors.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of magnetic-resonance-guided&#xD;
      radiofrequency ablation in treating patients who have primary kidney cancer, liver&#xD;
      metastases, or other solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether magnetic resonance image monitoring during radiofrequency interstitial&#xD;
           thermal ablation can accurately predict complete destruction of focal tumor along with&#xD;
           an adequate margin of normal tissue, as demonstrated by absence of growth on subsequent&#xD;
           imaging studies for a 1-year period, in patients with primary renal cell carcinoma,&#xD;
           hepatic metastases, or other solid tumors.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease (localized hepatic metastases vs&#xD;
      primary renal neoplasms vs solid tumors in other sites).&#xD;
&#xD;
      Patients undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.&#xD;
      Thermal ablation continues until the entire tumor is treated. Treatment ceases when the&#xD;
      entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition&#xD;
      approaches vital neurovascular structures.&#xD;
&#xD;
      Patients are followed at 2 weeks and at 3, 6, 9, and 12 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 28-39 patients will be accrued for this study within 22-36&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether magnetic resonance image monitoring during radiofrequency interstitial thermal ablation can accurately predict complete destruction of focal tumor along with an adequate margin of normal tissue.</measure>
    <time_frame>Patients are followed at 2 weeks and at 3, 6, 9, and 12 months.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Kidney Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radiofrequency ablation</intervention_name>
    <description>Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>thermal ablation therapy</intervention_name>
    <description>Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of primary renal cell carcinoma, hepatic metastases, or other solid tumor&#xD;
             meeting the following criteria:&#xD;
&#xD;
               -  Not amenable to curative or substantial palliative therapy OR&#xD;
&#xD;
               -  Failed chemotherapy or biological response modifier therapy OR&#xD;
&#xD;
               -  Unlikely to benefit from conventional chemotherapy&#xD;
&#xD;
               -  No more than 5 measurable metastatic masses in the liver&#xD;
&#xD;
                    -  No greater than 5 cm in diameter&#xD;
&#xD;
               -  Other tumor sites allowed if location and size amenable to ablation therapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 4 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Granulocyte count at least 1,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 8.0 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  No untreated bleeding diathesis&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  PT no greater than 13.5 seconds&#xD;
&#xD;
          -  PT/PTT normal if prior warfarin or heparin use&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No implanted pacemaker, incompatible aneurysm clip, or other device that would&#xD;
             preclude magnetic resonance imaging&#xD;
&#xD;
          -  No myocardial infarction within the past 6 weeks&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  No serious active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior biological response modifier therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to study lesion&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 7 days since prior nonsteroidal antiinflammatory drugs or aspirin&#xD;
&#xD;
          -  At least 1 hour since prior heparin&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
          -  No concurrent investigational drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John R. Haaga, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>September 11, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 9, 2010</last_update_submitted>
  <last_update_submitted_qc>June 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>John R. Haaga, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

